Ex-4 treatment upregulates the expression of the proteins critical for mitochondrial biogenesis, including peroxisome proliferator-activated receptor- coactivator-1 (PGC-1), nuclear respiratory factor-1 (NRF-1), and transcription factor a, mitochondrial (Tfam)
Rotate between abdomen, thigh, and upper arm sites
When dose reduction is appropriate Phase 3 trials include provisions for dose reduction: Gastrointestinal adverse events or inadequate oral intake may warrant stepping down to a lower dose level see Retatrutide Side Effects for incidence rates by dose BMI reaching 22 kg/m or below , or perceived excessive weight loss, allows dose reduction Treatment is discontinued at BMI 18.5 kg/m or below How Often and When to Take Retatrutide Injection frequency once weekly by subcutaneous injection, on the same day each week
For obesity management , GLP-1 receptor agonists such as semaglutide 2.4mg (Wegovy) are recommended by NICE (TA875) only through specialist weight management services for people with specific BMI thresholds and weight-related complications
When the fat compartments shrink, the overlying skin loses its firmness, resulting in a deflated appearance and skin laxity
Most of our patients begin seeing measurable results within the first 4 to 8 weeks
